Clinical Pearls for Community Oncologists: Optimizing ADC Use in TNBC

Antibody–drug conjugates (ADCs) have transformed the treatment landscape for triple-negative breast cancer (TNBC), offering targeted efficacy with manageable toxicity. For community oncologists, several practical insights can guide optimal use. First, careful patient selection based on HER2 expression, prior therapies, and comorbidities is essential to maximize benefit. Proactive adverse event management—including monitoring for neutropenia, interstitial lung disease, ocular toxicity, and stomatitis—helps maintain dose intensity and treatment continuity. Understanding sequencing strategies and potential combinations with immunotherapy or targeted agents can further enhance outcomes. Additionally, staying informed about emerging ADCs, novel targets, and evolving clinical trial data enables timely adoption of new options. By integrating these strategies, community oncologists can deliver personalized, evidence-based care, improve tolerability, and optimize clinical outcomes for patients with advanced TNBC.